Navigation Links
Silence Therapeutics Signs Collaboration With Mirna Therapeutics to Evaluate Delivery of Novel microRNA Therapeutics
Date:10/23/2011

/p>

About Silence Therapeutics plc (http://www.silence-therapeutics.com)

Silence Therapeutics plc (AIM: SLN) is a leading biotechnology company dedicated to the discovery, development and delivery of targeted, systemic RNA interference (RNAi) therapeutics for the treatment of serious diseases. Silence offers one of the most comprehensive short interfering RNA (siRNA) therapeutic platforms available today based on a strong intellectual property portfolio and large clinical safety database. Silence's clinical siRNA product pipeline is one of the broadest in the industry. The Company possesses multiple proprietary siRNA delivery technology platforms including AtuPLEX™, DACC and DBTC. AtuPLEX enables the broad functional delivery of siRNA molecules to targeted diseased tissues and cells, while increasing their bioavailability and intracellular uptake. The DACC delivery system allows functional delivery of siRNA molecules selectively to the lung endothelium with a long duration of target mRNA and protein knock-down. The DBTC delivery system enables functional delivery of siRNA molecules selectively to liver cells including hepatocytes. Additionally, the Company has a platform of novel siRNA molecules based around its AtuRNAi chemical modification technology, which provides a number of advantages over conventional siRNA molecules. Silence's unique RNAi assets also include structural features for RNAi molecules and specific design rules for increased potency and reduced off-target effects of siRNA sequences.

The Company's lead internal drug candidate is Atu027, a liposomal formulation in clinical development for systemic cancer indications and one of the most clinically advanced RNAi therapeutic candidates in the area of oncology. Atu027 incorporates two of the Company's technologies, AtuRNAi and AtuPLEX. Silence is currently conducting an open-label, single
'/>"/>

SOURCE Silence Therapeutics Plc
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Silence Therapeutics Issued Japanese Patent Covering its Core RNA Interference (RNAi) Technology
2. Silence Therapeutics Lead RNA Interference Therapeutic Prevents Spread of Cancer to Lungs
3. Silence Therapeutics Receives Comprehensive Protection for RNAi Structural Modification Technology in Single European Patent
4. Silence Therapeutics Partner Quark Signs Exclusive Option Agreement With Novartis for Development and Commercialisation of QPI-1002
5. Silence Therapeutics Expands RNAi Structural Modification IP Portfolio With Issuance of New U.S. Patent
6. Silence Therapeutics Issued Novel RNAi Patent Covering High-Value Cancer Target in United States
7. Silence Therapeutics Appoints New Vice President of Research
8. Silence Therapeutics to Present at 12th Annual BIO CEO & Investor Conference
9. National Ovarian Cancer Coalition and PureOlogy to Host First Annual NOCC and PureOlogys Walk to Break the Silence on Ovarian Cancer
10. Amsterdam Molecular Therapeutics Receives Opinion on Re-examination of Glybera® Marketing Authorisation Application
11. Regulus Therapeutics and Collaborators Publish New Pre-Clinical Data on microRNA-33 Demonstrating Key Role in Cholesterol Homeostasis and Fatty Acid Metabolism
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Ill. , Jan. 15, 2014  Bill Jacobs Automotive, a ... , is teaming up with the Heartland Blood Center and ... blood drive. The drive takes place Saturday, Jan. 18 at ... - 2 p.m. (Photo: http://photos.prnewswire.com/prnh/20140115/MN46637 )  ...
(Date:1/15/2014)... 2014   Niagara Thermal Products is proud to ... Technologies LLC ("B3") as the critical thermal component supplier ... the Army Corps of Engineers.  B3 has developed the ... contaminants and destroys VOCs and other chemical pollutants, allergens ...
(Date:1/15/2014)... Cynvenio, a cancer diagnostics company focused on ... of tumor cells in the bloodstream, today announced that ... support application powered by CollabRx, Inc. , Available ... Therapy Finder will provide breast cancer patients and their ...
(Date:1/15/2014)... 2014 ­ RedBrick Health , a fast-growing leader ... announces that EmblemHealth , the New ... now providing the RedBrick Compass health assessment, combined with ... of its members. EmblemHealth is among the first health ...
Breaking Biology Technology:Join the Bill Jacobs Auto blood drive and receive a free oil change 2Niagara Thermal Products LLC Selected as Critical Supplier for Buffalo BioBlower Air Purification Systems 2Cynvenio Offers New Breast Cancer Therapy Finder Application for its ClearID Breast Cancer Genomic Test 2Cynvenio Offers New Breast Cancer Therapy Finder Application for its ClearID Breast Cancer Genomic Test 3EmblemHealth Selects RedBrick Health to Power its Next-Generation Health Engagement and Behavior Change System 2EmblemHealth Selects RedBrick Health to Power its Next-Generation Health Engagement and Behavior Change System 3
... Which Drugs Are More Effective, According to a New ... Report ... Resources, one of the,world,s leading research and advisory firms focusing ... generics-,dominated fluoxetine lead first-line therapy in the treatment of major,depression. ...
... ... Trend at AdvaMed 2007, WASHINGTON, Oct. 2 ... Hisey will lead a discussion on,the intricacies of convergence partnerships tomorrow ... and pressures to reduce health care costs, companies in all sectors,of ...
... - AEterna Zentaris Inc.,(TSX: AEZ; Nasdaq: AEZS), a ... will announce today at 11: 00 a.m. Eastern,Time, ... hosted by,President and Chief Executive Officer, David J. ... Company,s pipeline and business operations,along with key elements ...
Cached Biology Technology:Forest Laboratories' Lexapro and Generics-Dominated Fluoxetine Lead First-Line Therapy in the Treatment for Major Depression 2Forest Laboratories' Lexapro and Generics-Dominated Fluoxetine Lead First-Line Therapy in the Treatment for Major Depression 3Deloitte Leadership Offers Crucial Convergence Considerations for Life Sciences Companies 2Deloitte Leadership Offers Crucial Convergence Considerations for Life Sciences Companies 3Deloitte Leadership Offers Crucial Convergence Considerations for Life Sciences Companies 4AEterna Zentaris Announces Outcome of Management's Strategic Review 2AEterna Zentaris Announces Outcome of Management's Strategic Review 3AEterna Zentaris Announces Outcome of Management's Strategic Review 4
(Date:4/17/2014)... anthrax detection cartridge developed at Sandia National Laboratories and ... easier, faster and cheaper. , Bacillus anthracis ... in soils all over the world and can cause ... animals. The bacteria can survive in harsh conditions for ... may occur through skin contact, inhalation of spores or ...
(Date:4/17/2014)... in bone marrow need to produce hydrogen sulfide in ... to a new study from the Center for Craniofacial ... of USC. , Professor Songtao Shi, principal investigator on ... by the cells governs the flow of calcium ions. ... that results in osteogenesis, or the creation of new ...
(Date:4/17/2014)... Europe, Asia and the United States are spreading across ... native honeybee populations at this time, according to an ... Nosema microsporidia and Varroa mites., ... these invasive pests, which suggests to us that the ... the United States currently are not necessary in East ...
Breaking Biology News(10 mins):Pocket-sized anthrax detector aids global agriculture 2Pocket-sized anthrax detector aids global agriculture 3East African honeybees are safe from invasive pests… for now 2East African honeybees are safe from invasive pests… for now 3
... disease after HIV infection is inversely correlated with the presence ... cell family and the major producers of type 1 interferon ... to successful control of HIV. In a paper appearing ... the November issue of the Journal of Clinical Investigation, Nina ...
... recently opened pulp mill in Chile has devastated one ... its famed population of black-necked swans, along with most ... Monday. , "What was probably the largest population of ... out in less than a year. It is an ...
... don't grow, a researcher at MIT's Picower Institute for Learning ... Library of Science (PLoS) Biology that structural remodeling of neurons ... finding means that it may one day be possible to ... spinal cord injury, such as the one that paralyzed the ...
Cached Biology News:Pulp mill devastates swans' sanctuary in Chile 2MIT researcher finds neuron growth in adult brain 2MIT researcher finds neuron growth in adult brain 3
...
... BacVector Insect Cell Medium is optimized ... Ea4 Insect Cells. In this protein-free medium, ... 1 * 107 cells/ml with viabilities above ... plaque assays, where color from X-gluc staining ...
...
...
Biology Products: